GNRO Stock Overview
A clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
GeNeuro SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €1.90 |
52 Week High | €2.10 |
52 Week Low | €0.94 |
Beta | 0.27 |
1 Month Change | 30.14% |
3 Month Change | 50.79% |
1 Year Change | 10.47% |
3 Year Change | -43.45% |
5 Year Change | -44.44% |
Change since IPO | -84.46% |
Recent News & Updates
Shareholder Returns
GNRO | FR Biotechs | FR Market | |
---|---|---|---|
7D | -0.5% | 0.5% | -1.3% |
1Y | 10.5% | -16.1% | 5.2% |
Return vs Industry: GNRO exceeded the French Biotechs industry which returned -14.9% over the past year.
Return vs Market: GNRO exceeded the French Market which returned 7% over the past year.
Price Volatility
GNRO volatility | |
---|---|
GNRO Average Weekly Movement | 7.6% |
Biotechs Industry Average Movement | 6.6% |
Market Average Movement | 4.4% |
10% most volatile stocks in FR Market | 9.6% |
10% least volatile stocks in FR Market | 2.4% |
Stable Share Price: GNRO's share price has been volatile over the past 3 months.
Volatility Over Time: GNRO's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 17 | Jesus Martin-Garcia | www.geneuro.com |
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family; treats type 1 diabetes; and treats chronic inflammatory demyelinating polyneuropathy. It also developing GNK301.
GeNeuro SA Fundamentals Summary
GNRO fundamental statistics | |
---|---|
Market cap | €56.23m |
Earnings (TTM) | -€14.76m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.8x
P/E RatioIs GNRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GNRO income statement (TTM) | |
---|---|
Revenue | €0 |
Cost of Revenue | €0 |
Gross Profit | €0 |
Other Expenses | €14.76m |
Earnings | -€14.76m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.50 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -93.4% |
How did GNRO perform over the long term?
See historical performance and comparison